GE HealthCare Technologies Inc. (NASDAQ:GEHC) Receives $97.67 Consensus Price Target from Brokerages

GE HealthCare Technologies Inc. (NASDAQ:GEHC) has been given a consensus recommendation of “Moderate Buy” by the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $97.67.

Several research analysts have issued reports on the company. Wells Fargo & Company raised their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Citigroup raised their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Finally, Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price objective for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th.

Institutional Trading of GE HealthCare Technologies

A number of large investors have recently added to or reduced their stakes in the company. Cherry Creek Investment Advisors Inc. increased its stake in GE HealthCare Technologies by 0.3% in the 4th quarter. Cherry Creek Investment Advisors Inc. now owns 37,351 shares of the company’s stock worth $2,920,000 after acquiring an additional 114 shares during the last quarter. Independence Bank of Kentucky increased its stake in GE HealthCare Technologies by 6.0% in the 4th quarter. Independence Bank of Kentucky now owns 2,018 shares of the company’s stock worth $158,000 after acquiring an additional 114 shares during the last quarter. Haverford Trust Co increased its stake in GE HealthCare Technologies by 2.4% in the 4th quarter. Haverford Trust Co now owns 4,896 shares of the company’s stock worth $383,000 after acquiring an additional 115 shares during the last quarter. Tandem Capital Management Corp ADV increased its stake in GE HealthCare Technologies by 0.4% in the 4th quarter. Tandem Capital Management Corp ADV now owns 28,210 shares of the company’s stock worth $2,205,000 after acquiring an additional 118 shares during the last quarter. Finally, Arcus Capital Partners LLC increased its stake in GE HealthCare Technologies by 3.0% in the 4th quarter. Arcus Capital Partners LLC now owns 4,113 shares of the company’s stock worth $322,000 after acquiring an additional 119 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Trading Down 0.6 %

GE HealthCare Technologies stock opened at $90.57 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. GE HealthCare Technologies has a one year low of $74.51 and a one year high of $94.80. The stock has a market capitalization of $41.42 billion, a PE ratio of 20.92, a price-to-earnings-growth ratio of 3.19 and a beta of 1.15. The business’s fifty day moving average is $85.26 and its 200 day moving average is $85.96.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.26 by $0.19. The company had revenue of $5.32 billion for the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. On average, sell-side analysts predict that GE HealthCare Technologies will post 4.68 EPS for the current year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.